Agenus (AGEN)

Agenus Stock Analysis & Ratings

AGEN Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.25 - $6.79
Previous Close$1.84
Average Volume (3M)4.56M
Market CapN/A
Enterprise ValueN/A
P/E Ratio-19.8
Next EarningsAug 11, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
Smart Score2



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Agenus’s price range in the past 12 months?
Agenus lowest stock price was $1.25 and its highest was $6.79 in the past 12 months.
    What is Agenus’s market cap?
    Currently, no data Available
    What is Agenus’s price target?
    Currently, no data Available
    What do analysts say about Agenus?
    Agenus’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
      When is Agenus’s upcoming earnings report date?
      Agenus’s upcoming earnings report date is Aug 11, 2022 which is in 43 days.
        How were Agenus’s earnings last quarter?
        Agenus released its earnings results on May 10, 2022. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.298 by $0.108.
          Is Agenus overvalued?
          According to Wall Street analysts Agenus’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Agenus pay dividends?
            Agenus does not currently pay dividends.
            What is Agenus’s EPS estimate?
            Agenus’s EPS estimate is -$0.23.
              How many shares outstanding does Agenus have?
              Agenus has 282,859,070 shares outstanding.
                What happened to Agenus’s price movement after its last earnings report?
                Agenus reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.298. Following the earnings report the stock price went up 9.211%.
                  Which hedge fund is a major shareholder of Agenus?
                  Among the largest hedge funds holding Agenus’s share is Oracle Investment Management Inc. It holds Agenus’s shares valued at 21M.


                    Agenus Stock Analysis

                    Smart Score
                    Price Target
                    No data currently available
                    The Agenus stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                    Learn more about TipRanks Smart Score

                    Company Description


                    Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.

                    Similar Stocks
                    Price & Change
                    Merck & Company
                    Northwest Biotherapeutics
                    ImmunoCellular Therapeutics

                    Popular Stocks

                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis